TCR2 Therapeutics is engineering T cell receptors (TCRs) to treat solid tumors. T cells are potent components of the immune system that identify tumor cells through their TCRs and direct the immune system to fight and clear them. TCR2 is expanding the range of TCRs and optimizing them for longer persistence in the body, better response to relapse due to antigen escape and to create a memory phenotype. Through this approach, TCR2 is creating TCR Fusion Construct T cells (TRuC-T cells) that involves engineering a patient’s T cells for a powerful, yet controlled response against cancer cells. With promising preclinical and clinical studies, TCR2 is building a robust pipeline for solid and hematologic cancers.
Claim company profile to post jobs directly on this page and this website.